Introduction: Rheumatoid arthritis (RA) is a chronic, systemic, autoimmune disease, which affects joints and extra-articular structures. Nowadays, the armamentarium of therapeutic options is progressively expanding and embraces several mechanisms of action: TNF inhibition, B-cell depletion, T-cell co-stimulation inhibition, IL-6 blockade, and JAK-inhibition. Granulocyte-Monocyte-Colony-Stimulating-Factor (GM-CSF) is a mediator acting as a cytokine with a proven pathogenetic role in RA, providing a potential alternative target for the management of the disease. Mavrilimumab is a monoclonal antibody against GM-CSF receptor, which has been successfully tested in RA patients. Areas covered: Beginning with a description of the preclinical evidence and the rationale for GM-CSF blockade in RA, this review will provide a wide overview of mavrilimumab efficacy and safety profile by analyzing phase I/II RCTs conducted in patients with moderate to severe RA. Expert opinion: According to the promising results from phase I-II RCTs, mavrilimumab could be considered as an additional therapeutic option for RA patients multi-resistant to the available targeted drugs. However, the optimal dose and the profile of this new drug should be confirmed in phase III RCTs before the marketing.

Mavrilimumab: a unique insight and update on the current status in the treatment of rheumatoid arthritis / C. Crotti, M. Biggioggero, A. Becciolini, E. Agape, E.G. Favalli. - In: EXPERT OPINION ON INVESTIGATIONAL DRUGS. - ISSN 1354-3784. - 28:7(2019), pp. 573-581. [10.1080/13543784.2019.1631795]

Mavrilimumab: a unique insight and update on the current status in the treatment of rheumatoid arthritis

C. Crotti
Primo
Writing – Original Draft Preparation
;
M. Biggioggero
Secondo
;
A. Becciolini;E. Agape
Penultimo
;
E.G. Favalli
Ultimo
Writing – Review & Editing
2019

Abstract

Introduction: Rheumatoid arthritis (RA) is a chronic, systemic, autoimmune disease, which affects joints and extra-articular structures. Nowadays, the armamentarium of therapeutic options is progressively expanding and embraces several mechanisms of action: TNF inhibition, B-cell depletion, T-cell co-stimulation inhibition, IL-6 blockade, and JAK-inhibition. Granulocyte-Monocyte-Colony-Stimulating-Factor (GM-CSF) is a mediator acting as a cytokine with a proven pathogenetic role in RA, providing a potential alternative target for the management of the disease. Mavrilimumab is a monoclonal antibody against GM-CSF receptor, which has been successfully tested in RA patients. Areas covered: Beginning with a description of the preclinical evidence and the rationale for GM-CSF blockade in RA, this review will provide a wide overview of mavrilimumab efficacy and safety profile by analyzing phase I/II RCTs conducted in patients with moderate to severe RA. Expert opinion: According to the promising results from phase I-II RCTs, mavrilimumab could be considered as an additional therapeutic option for RA patients multi-resistant to the available targeted drugs. However, the optimal dose and the profile of this new drug should be confirmed in phase III RCTs before the marketing.
Biologic agents; efficacy; Granulocyte-macrophage colony-stimulating factor; mavrilimumab; rheumatoid arthritis; safety
Settore MED/16 - Reumatologia
2019
Article (author)
File in questo prodotto:
File Dimensione Formato  
Crotti-Mavrilimumab- a unique insight and update on the current status in the treatment of rheumatoid arthritis-2019-Expert Opinion on Investigational Drugs.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 1.17 MB
Formato Adobe PDF
1.17 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/911049
Citazioni
  • ???jsp.display-item.citation.pmc??? 13
  • Scopus 31
  • ???jsp.display-item.citation.isi??? 26
social impact